Last reviewed · How we verify
BET Inhibitor
BET Inhibitor is a BET inhibitor Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 2 development for T-cell lymphoma, Multiple myeloma.
BET inhibitor targets bromodomain and extra-terminal domain (BET) proteins
BET inhibitor targets bromodomain and extra-terminal domain (BET) proteins Used for T-cell lymphoma, Multiple myeloma.
At a glance
| Generic name | BET Inhibitor |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | BET inhibitor |
| Target | BET proteins |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BET proteins play a key role in the regulation of gene transcription, and their inhibition has been shown to have anti-inflammatory and anti-cancer effects.
Approved indications
- T-cell lymphoma
- Multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors (PHASE1, PHASE2)
- Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors (PHASE1)
- Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer (PHASE1)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers (PHASE1)
- Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (PHASE1)
- Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BET Inhibitor CI brief — competitive landscape report
- BET Inhibitor updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about BET Inhibitor
What is BET Inhibitor?
How does BET Inhibitor work?
What is BET Inhibitor used for?
Who makes BET Inhibitor?
What drug class is BET Inhibitor in?
What development phase is BET Inhibitor in?
What are the side effects of BET Inhibitor?
What does BET Inhibitor target?
Related
- Drug class: All BET inhibitor drugs
- Target: All drugs targeting BET proteins
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for T-cell lymphoma
- Indication: Drugs for Multiple myeloma
- Compare: BET Inhibitor vs similar drugs
- Pricing: BET Inhibitor cost, discount & access